FDA blazes the transparency trail
This article was originally published in Scrip
There has been no shortage of moves to increase transparency at regulatory agencies in the past year or so. The European Medicines Agency has brought in new policies on access to documents and clinical trial data, while side-effect data is to be made more easily available. The French regulator, meanwhile, has promised zero tolerance on conflicts of interest among its committee members and more transparency on publishing minutes of its committee meetings.
You may also be interested in...
The UK has used a special legislative process to temporarily authorize the use of the BNT-162b2 vaccine, with the first 800,000 shots expected to be delivered within days.
A package of health proposals intended to build up the EU’s resilience to health threats while strengthening the competitiveness of Europe’s pharmaceutical industry and ensuring access to affordable drugs takes a major step through the legislative process this week.
European Commission proposals for strengthening intellectual property protections in the EU, particularly the supplementary protection certificate (SPC) system, have been broadly welcomed by Europe’s brand industry. But the medical NGO, MSF, says the SPC proposals run counter to the commission’s own efforts to improve access to medicines.